Bert Wagner

Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial

John Foley, Gilles Defer, Lana Zhovtis Ryerson et al. · The Lancet Neurology · 2022 · 110 citations

Medicine, Pharmacology, Pharmacotherapy +11

Electrocardiographic assessments and cardiac events after fingolimod first dose – a comprehensive monitoring study

Volker Limmroth, Tjalf Ziemssen, Michael Lang et al. · BMC Neurology · 2017 · 23 citations · Full text

Medicine, Cardiology, Pharmacology +17

Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting

María Trojano, Helmut Butzkueven, Ludwig Kappos et al. · Multiple Sclerosis and Related Disorders · 2018 · 19 citations · Full text

Medicine, Neurology, Pharmacotherapy +17